TNF and tuberculosis: The subsequent implementation of screening protocols has significantly reduced TB rates, contributing to the lower incidence observed in LTE studies and real-world applications of IFX, ADA, and ETN, as well as with newer anti-TNF-α agents like golimumab and certolizumab pegol (52).